Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2013

01-06-2013 | Urologic Oncology

Effect of Nodal Metastases on Cancer-specific Mortality After Cytoreductive Nephrectomy

Authors: Quoc-Dien Trinh, MD, Shyam Sukumar, MD, Jan Schmitges, MD, Marco Bianchi, MD, Maxine Sun, BSc, Shahrokh F. Shariat, MD, Jesse D. Sammon, DO, Claudio Jeldres, MD, Kevin C. Zorn, MD, Paul Perrotte, MD, Markus Graefen, MD, Craig G. Rogers, MD, James O. Peabody, MD, Mani Menon, MD, Pierre I. Karakiewicz, MD

Published in: Annals of Surgical Oncology | Issue 6/2013

Login to get access

Abstract

Background

Relatively few reports have described the outcomes of patients with node-positive renal cell carcinoma (RCC) in the presence of distant metastases. We examined the outcomes of these patients in a large population-based cohort and examined the ability of standard risk factors to predict cancer-specific mortality (CSM).

Methods

Using the Surveillance, Epidemiology, and End Results database, 1415 RCC patients with distant metastases undergoing cytoreductive nephrectomy (CNT) were identified. Univariable and multivariable analyses addressed CSM to identify independent predictors of CSM. First, the effect of nodal disease on CSM and overall mortality (OM) was estimated in patients with metastatic disease (N0M1 vs. N1M1). Then, we examined the effect of the number of removed nodes and the number of positive nodes on CSM to quantify the effect on mortality, if any, of the increasing burden of nodal disease.

Results

Actuarial survival estimates demonstrated that for patients with nodal disease 40.2, 23.5 and 11.5 % of patients survived at 12, 24 and 60 months after nephrectomy. In Kaplan–Meier analyses, patients with N1M1 disease had a significantly worse CSM when compared to patients with N0M1 disease (log rank p < 0.001). In multivariable analyses, N1M1 had a 68 and 69 % increase in CSM and OM (vs. N0M1 disease) while, for every additional positive node, CSM and OM increased by 5.1 and 5.6 %.

Conclusions

In patients undergoing CNT, the burden of nodal disease is an independent predictor of CSM, with an incremental effect of every additional positive node.
Literature
1.
Sun M, Thuret R, Abdollah F, et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol. 2011;59:135–41.PubMedCrossRef
2.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
3.
Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166:1611–23.PubMedCrossRef
4.
Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–9.PubMedCrossRef
5.
Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966–70.PubMedCrossRef
6.
Lughezzani G, Capitanio U, Jeldres C, et al. Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective. Cancer. 2009;115:5680–7.PubMedCrossRef
7.
8.
Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655–63.PubMedCrossRef
9.
Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612–24.PubMedCrossRef
10.
Steiner T, Knels R, Schubert J. Prognostic significance of tumour size in patients after tumour nephrectomy for localised renal cell carcinoma. Eur Urol. 2004;46:327–30.PubMedCrossRef
11.
Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166:63–7.PubMedCrossRef
12.
Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. 2005;173:48–51.PubMedCrossRef
13.
Patard JJ, Leray E, Cindolo L, et al. Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol. 2004;172:858–62.PubMedCrossRef
14.
Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163:1090–5.PubMedCrossRef
15.
Whitson JM, Harris CR, Reese AC, Meng MV. Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases. J Urol. 2011;185:1615–20.PubMedCrossRef
16.
Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol. 2001;166:68–72.PubMedCrossRef
17.
Canfield SE, Kamat AM, Sanchez-Ortiz RF, Detry M, Swanson DA, Wood CG. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1–2M0): the impact of aggressive surgical resection on patient outcome. J Urol. 2006;175:864–9.PubMedCrossRef
18.
Karakiewicz PI, Lewinshtein DJ, Chun FK, et al. Tumor size improves the accuracy of TNM predictions in patients with renal cancer. Eur Urol. 2006;50:521–8.PubMedCrossRef
19.
Capitanio U, Jeldres C, Patard JJ, et al. Stage-specific effect of nodal metastases on survival in patients with non-metastatic renal cell carcinoma. BJU Int. 2009;103:33–7.PubMedCrossRef
20.
Culp SH, Tannir NM, Abel EJ, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010;116:3378–88.PubMedCrossRef
21.
Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol. 2001;19:425–31.PubMed
22.
Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol. 2003;21:1214–22.PubMedCrossRef
23.
Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol. 2003;21:3133–40.PubMedCrossRef
24.
Atzpodien J, Schmitt E, Gertenbach U, et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer. 2005;92:843–6.PubMedCrossRef
25.
Capitanio U, Shariat SF, Isbarn H, et al. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol. 2009;56:1–9.PubMedCrossRef
26.
Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007;109:1763–8.PubMedCrossRef
27.
Kutikov A, Egleston BL, Wong YN, Uzzo RG. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol. 2010;28:311–7.PubMedCrossRef
28.
Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a population-based cohort study. Cancer. 2009;115:2863–71.PubMedCrossRef
Metadata
Title
Effect of Nodal Metastases on Cancer-specific Mortality After Cytoreductive Nephrectomy
Authors
Quoc-Dien Trinh, MD
Shyam Sukumar, MD
Jan Schmitges, MD
Marco Bianchi, MD
Maxine Sun, BSc
Shahrokh F. Shariat, MD
Jesse D. Sammon, DO
Claudio Jeldres, MD
Kevin C. Zorn, MD
Paul Perrotte, MD
Markus Graefen, MD
Craig G. Rogers, MD
James O. Peabody, MD
Mani Menon, MD
Pierre I. Karakiewicz, MD
Publication date
01-06-2013
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 6/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2806-4

Other articles of this Issue 6/2013

Annals of Surgical Oncology 6/2013 Go to the issue

Colorectal Cancer

Combined Modality Therapy for Rectal Cancer: Too Much Too Often?

Colorectal Cancer

Long-term Results of Rectal Cancer Surgery with a Systematical Operative Approach

Bone and Soft Tissue Sarcomas

Predictors of Survival and Recurrence in Primary Leiomyosarcoma

Breast Oncology

Breast Cancer Subtype and Distant Recurrence after Ipsilateral Breast Tumor Recurrence

Healthcare Policy and Outcomes

Readmission After Pancreatic Resection is not an Appropriate Measure of Quality

Endocrine Tumors

Technical and Oncologic Safety of Robotic Thyroid Surgery